Show simple item record

dc.contributor.authorHammerschlag, M R
dc.date.accessioned2023-06-30T17:16:50Z
dc.date.available2023-06-30T17:16:50Z
dc.date.issued2000-11
dc.identifier.citationHammerschlag MR. Chlamydia pneumoniae and the lung. Eur Respir J. 2000 Nov;16(5):1001-7. doi: 10.1183/09031936.00.16510010. PMID: 11153568.en_US
dc.identifier.issn0903-1936
dc.identifier.pmid11153568
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10354
dc.description.abstractChlamydia pneumoniae is a frequently occurring respiratory pathogen affecting all age groups. It may cause 5-20% of community-acquired pneumonias in adults and children. The organism has also been implicated as an infectious trigger for asthma. Furthermore, new studies suggest that it may play a role in the pathogenesis of several chronic diseases including atherosclerosis. However, despite the growing significance of C. pneumoniae as a pathogen, progress is hampered by the lack of standardized diagnostic methods including serology and polymerase chain reaction. This makes it practically impossible for the practitioner to make a specific microbiological diagnosis. The lack of standardized methods has also had an adverse effect on treatment trials. The dependence on serology for diagnosis in treatment studies has generated some questionable results. Unless cultures are performed, microbiological efficacy cannot be assessed and it may never be possible to survey for or document the emergence of resistance.
dc.language.isoenen_US
dc.relation.urlhttps://erj.ersjournals.com/content/16/5/1001.longen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleChlamydia pneumoniae and the lung.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleThe European respiratory journalen_US
dc.source.volume16
dc.source.issue5
dc.source.beginpage1001
dc.source.endpage7
dc.source.countryEngland
dc.description.versionVoRen_US
refterms.dateFOA2023-06-30T17:16:50Z
html.description.abstractChlamydia pneumoniae is a frequently occurring respiratory pathogen affecting all age groups. It may cause 5-20% of community-acquired pneumonias in adults and children. The organism has also been implicated as an infectious trigger for asthma. Furthermore, new studies suggest that it may play a role in the pathogenesis of several chronic diseases including atherosclerosis. However, despite the growing significance of C. pneumoniae as a pathogen, progress is hampered by the lack of standardized diagnostic methods including serology and polymerase chain reaction. This makes it practically impossible for the practitioner to make a specific microbiological diagnosis. The lack of standardized methods has also had an adverse effect on treatment trials. The dependence on serology for diagnosis in treatment studies has generated some questionable results. Unless cultures are performed, microbiological efficacy cannot be assessed and it may never be possible to survey for or document the emergence of resistance.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalThe European respiratory journal
dc.identifier.issue5en_US


Files in this item

Thumbnail
Name:
1001.full.pdf
Size:
115.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International